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Abstract
Background: The development of effective frameworks that permit an accurate diagnosis of
tumors, especially in their early stages, remains a grand challenge in the field of bioinformatics. Our
approach uses statistical learning techniques applied to multiple antigen tumor antigen markers
utilizing the immune system as a very sensitive marker of molecular pathological processes. For
validation purposes we choose the intracranial meningioma tumors as model system since they
occur very frequently, are mostly benign, and are genetically stable.
Results: A total of 183 blood samples from 93 meningioma patients (WHO stages I-III) and 90
healthy controls were screened for seroreactivity with a set of 57 meningioma-associated antigens.
We tested several established statistical learning methods on the resulting reactivity patterns using
10-fold cross validation. The best performance was achieved by Naïve Bayes Classifiers. With this
classification method, our framework, called Minimally Invasive Multiple Marker (MIMM) approach,
yielded a specificity of 96.2%, a sensitivity of 84.5%, and an accuracy of 90.3%, the respective area
under the ROC curve was 0.957. Detailed analysis revealed that prediction performs particularly
well on low-grade (WHO I) tumors, consistent with our goal of early stage tumor detection. For
these tumors the best classification result with a specificity of 97.5%, a sensitivity of 91.3%, an
accuracy of 95.6%, and an area under the ROC curve of 0.971 was achieved using a set of 12 antigen
markers only. This antigen set was detected by a subset selection method based on Mutual
Information. Remarkably, our study proves that the inclusion of non-specific antigens, detected not
only in tumor but also in normal sera, increases the performance significantly, since non-specific
antigens contribute additional diagnostic information.
Conclusion: Our approach offers the possibility to screen members of risk groups as a matter of
routine such that tumors hopefully can be diagnosed immediately after their genesis. The early
detection will finally result in a higher cure- and lower morbidity-rate.
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Background
Tumor markers have been established to detect cancer, to
monitor cancer progression, to gauge responsiveness to
cancer treatment, and to provide insight into tumor devel-
opment. Molecular tumor markers can be grouped into
those that are identifiable in cancer cells and those that are
secreted as molecules into body fluids. Markers of the first
group encompass a wide spectrum including chromo-
some alterations, epigenetic DNA modifications, altered
RNA and protein expression, and protein modifications.
Detection of these markers requires the availability of can-
cer cells either obtained by tumor biopsies or by cancer
cell isolation from blood or other body fluids. The isola-
tion of cancer cells from body fluids and their use as mark-
ers is still in its early stages. The requirement of a tumor
biopsy limits the usefulness of such markers for early
detection of cancer. Among the second group of markers
the prostate specific antigen (PSA) is one of the few mark-
ers that are widely used in diagnosis and monitoring of
cancer [1].
However, even PSA has its severe limitations both in
detection and monitoring of prostate cancer. PSA is found
at high levels in approximately one third of the patients
without prostate cancer and its benefits for monitoring
after treatment remain controversial. Other serum mark-
ers like CA-15.3 for breast cancer and CA-19.9 for pancre-
atic cancer also have severe limitations [2]. Mass
spectroscopy is an up-to-date method to perform mini-
mally invasive cancer detection. A promising approach
using Matrix-Assisted Laser Desorption and Ionization
(MALDI) mass spectroscopy evaluated by 'peak probabil-
ity contrasts' revealed an accuracy of around 70% for ovar-
ian cancer [3]. Similar approaches for pancreatic cancer
performed slightly better with 88% sensitivity and 75%
specificity [4].
The onset of autoantibody signatures paved the way not
only for an improved diagnosis but also for a new kind of
monitoring of molecular processes in early tumor devel-
opment. Wang and co-workers [5] reported an autoanti-
body signature that allows for detection of prostate cancer
with 88.2% specificity and 81.6% sensitivity. However, a
limitation of the study was the use of many peptides with
weak homology to known proteins termed mimotopes.
Most recently, a study of ovarian cancer based on Bayesian
modeling showed similarly good results [6]. Prior to the
work by Erkanli and co-workers, we reported a first study
that identified a complex antibody response in patients
with meningioma [7]. Here, we present a novel concept
for a serum-based diagnosis of human tumors, especially
in their early stages of development. We chose meningi-
oma as a model, which is a priori not expected to trigger a
complex immune response: first meningioma is a gener-
ally benign tumor, and second it is genetically rather sta-
ble. Both factors do not favor a complex immune
response. Our approach permits the separation of menin-
gioma sera and normal sera with high specificity and sen-
sitivity, especially the separation of low-grade common
type meningiomas (WHO I) and normal controls. To
reach this high performance, we screened a total of 183
blood samples from 93 meningioma patients (WHO
stages I-III) and 90 individuals without known disease
(controls) for seroreactivity with a set of 57 meningioma-
associated antigens, i.e. antigens that were previously
found in sera of meningioma patients. Having screened
the 183 sera for these antigens we can group the meningi-
oma-associated antigens in two subgroups. Antigens that
are found in at least one of the 93 meningioma sera but
not in any of the 90 control sera are denoted as meningi-
oma-specific antigens. All antigens that are detected in at
least one of the 93 meningioma sera but also in at least
one of the 90 control sera are denoted as non-specific anti-
gens. We show in our study that the identification of men-
ingiomas, especially of low-grade common type
meningiomas, can be carried out with a significantly
decreased subset of antigens that includes meningioma-
specific as well as non-specific antigens.
Results
Mutual information of specific and non-specific antigens
One of the original goals of our project was to define a set
of meningioma-specific antigens that react with meningi-
oma sera but not with normal sera. With increasing
number of normal sera we found a decreasing number of
meningioma-specific antigens as indicated in Figure 1.
Notably, 49 of 57 antigens (86%) are detected in menin-
gioma sera and normal sera. One reason for the occur-
rence of non-specific antigens that can not be ruled out
completely is false positive antigen reactivity that is of
course unavoidable, especially when large numbers of
sera are analyzed. Any false positive antigen reactivity in a
normal serum possibly converts a specific antigen into a
non-specific antigen. However, our study shows that
some non-specific antigens entail even more information
for the diagnostic task than most of the specific antigens.
The mutual information as explained in 'Methods' offers
an appropriate measure of the information content of an
antigen. The mutual information values of all antigens are
shown in Figure 2. For meningioma-specific antigens the
mutual information ranges between 0.005 and 0.211 with
a mean value of 0.071 and a median of 0.05, whereas for
non-specific antigens it ranges between 0 and 0.141 with
a mean of 0.024 and a median of 0.018. As detailed in Fig-
ure 2 and Table 1, many non-specific antigens provide
even more mutual information than the majority of spe-
cific antigens. An example of such an antigen is NIT2 with
a mutual information value of 0.141. Notably, such a high
value is reached by only 1 of the 8 specific antigens. EvenBMC Bioinformatics 2006, 7:539 http://www.biomedcentral.com/1471-2105/7/539
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more, the difference of the mutual information of specific
and non-specific antigens was statistically not significant
(p-value of 0.09, unpaired two sample Wilcoxon Mann-
Whitney test). These findings support our hypothesis, that
non-specific antigens are suitable to enhance meningi-
oma detection.
Classification of sera using all antigens
We applied several standard classification methods to the
complete set of 93 meningioma and 90 normal sera that
were evaluated by using 10-fold cross validation. The first
Naïve Bayes approach, introduced in the 'Materials' sec-
tion, reached a specificity of 96.2% (95%-CI = [96.0%,
96.5%]), a sensitivity of 84.5% (95%-CI = [84.3%,
84.8%]), an accuracy of 90.3% (95%-CI = [90.1%,
90.4%]), and an AUC (area under the curve) value of
0.957 (95%-CI = [0.956, 0.957]). The classification result
of an arbitrary selected cross-validation run is shown in
Figure 3. The second Bayes approach showed similar per-
formance with a slightly increased specificity of 97.0%
(95%-CI = [96.8%, 97.1%]), a sensitivity of 83.8% (95%-
CI = [83.5%, 84.0%]), and an accuracy of 90.3% (95%-CI
= [90.1%, 90.4%]). We tested the data with several other
statistical learning methods (among them for example
Support Vector Machine, Linear Discriminant Analysis)
that yielded similar high-quality classification results,
indicating the high information content of the antigen
profiles. In order to validate our approaches, we carried
out 100 permutation tests by randomly permuting class
labels before classifying the 183 sera. The randomly per-
muted data yielded an averaged accuracy of 50%, which
corresponds to random guessing. The best random test
showed an accuracy of only 70%. An unpaired two-sam-
ple Wilcoxon Mann-Whitney test yielded a p-value of
smaller 10-10, asserting that the above classification results
can be attributed to the information content of the data
set and not to chance.
Classification of common type meningioma using all 
antigens
Since we are especially interested to perform accurate
diagnoses of early stages of tumor development we classi-
fied low-grade common type meningioma (WHO grade I)
sera versus normal sera. Using the complete set of 57 anti-
gens, common type meningioma sera are separated from
normal sera with a specificity of 98.6% (95%-CI =
[98.5%, 98.8%]), a sensitivity of 87.5% (95%-CI =
[87.3%, 87.6%]), and an accuracy of 95.2% (95%-CI =
[95.0%, 95.3%]). The respective AUC value was 0.967
(95%-CI = [0.966, 0.967]). For comparison, we also clas-
sified the sera of grade II and III tumor patients. The
results of the classification are summarized in Table 2. The
classification result of the first Naïve Bayes approach
shown in Figure 3 indicates that sera of common type and
atypical meningiomas can be clearly differentiated from
Mutual Information of 57 antigens Figure 2
Mutual Information of 57 antigens. Meningioma specific 
antigens are colored red. Notably, the antigen with the sec-
ond highest mutual information (NIT2) reacts with meningi-
oma and normal sera.
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Decrease of specific antigens Figure 1
Decrease of specific antigens. Decrease of meningioma-
specific antigens in the samples as a function of the number of 
screened normal sera computed by random sampling. Stand-
ard deviations of each subset size are shown as vertical green 
bars.BMC Bioinformatics 2006, 7:539 http://www.biomedcentral.com/1471-2105/7/539
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Table 1: Information about antigens and antigen reactivity
Gene Meningioma reac. (%) Normal reac. (%) Quotient Mutual Information Known Protein
NKTR 0,37 0,00 na 0,21 yes
NIT2 0,37 0,03 10,97 0,14 yes
KIAA1344 0,22 0,00 na 0,12 no
c13orf24 0,22 0,00 na 0,12 yes
SOX2 0,24 0,01 21,29 0,10 yes
TBC1D4 0,29 0,04 6,53 0,09 yes
NSEP1 0,15 0,00 na 0,08 yes
CDH12 0,32 0,09 3,63 0,06 yes
FLJ10747 0,30 0,08 3,87 0,06 yes
C6orf153 0,15 0,01 13,55 0,06 no
USP37 0,13 0,01 11,61 0,04 yes
SART1 0,39 0,18 2,18 0,04 yes
LMO3 0,14 0,02 6,29 0,04 yes
SC65 0,22 0,07 3,23 0,03 yes
TBC1D2 0,42 0,22 1,89 0,03 yes
TNKS 0,13 0,02 5,81 0,03 yes
ANK2 0,17 0,04 3,87 0,03 yes
DLD 0,15 0,03 4,52 0,03 yes
MLLT4 0,04 0,17 0,26 0,03 yes
KIAA0555 0,40 0,21 1,88 0,03 yes
SFRS11 0,27 0,12 2,20 0,03 yes
NIN 0,20 0,08 2,63 0,02 yes
MGEA5 0,15 0,04 3,39 0,02 yes
PC326 0,32 0,17 1,94 0,02 yes
MGEA5s 0,13 0,03 3,87 0,02 yes
MGEA11 0,04 0,00 na 0,02 yes
RTN4 0,16 0,30 0,54 0,02 yes
PARP1 0,33 0,19 1,76 0,02 yes
HNRPA1 0,41 0,26 1,60 0,02 yes
MOCS1 0,22 0,10 2,15 0,02 yes
KIAA0999 0,15 0,06 2,71 0,02 yes
MGEA6 0,16 0,07 2,42 0,02 yes
SWAP70 0,24 0,12 1,94 0,02 yes
ARHGAP18 0,03 0,00 na 0,02 yes
TNKS2 0,60 0,46 1,32 0,02 yes
RBPSUH 0,23 0,33 0,68 0,01 yes
SMARCA4 0,02 0,07 0,32 0,01 yes
CCDC2 0,12 0,06 2,13 0,01 yes
SASH1 0,22 0,13 1,61 0,01 yes
TRA1 0,18 0,11 1,65 0,01 yes
MAP4K4 0,01 0,00 na 0,01 yes
PAFAH1B1 0,01 0,00 na 0,01 yes
IGFBP5 0,13 0,08 1,66 0,01 yes
CTGF 0,11 0,07 1,61 0,00 yes
BRAP 0,54 0,48 1,13 0,00 yes
MGEA14 0,10 0,07 1,45 0,00 yes
NCOA7 0,13 0,17 0,77 0,00 yes
TPM3 0,11 0,08 1,38 0,00 yes
INA 0,19 0,16 1,24 0,00 yes
FALZ 0,02 0,01 1,94 0,00 yes
c6ORF60 0,27 0,30 0,90 0,00 no
ZBTB5 0,10 0,08 1,24 0,00 yes
C9orf112 0,22 0,19 1,14 0,00 no
HSPCB 0,12 0,10 1,18 0,00 yes
APLP1 0,05 0,07 0,81 0,00 yes
PRC1 0,28 0,26 1,09 0,00 yes
SNRK 0,27 0,29 0,93 0,00 yesBMC Bioinformatics 2006, 7:539 http://www.biomedcentral.com/1471-2105/7/539
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Table 2: Classification results
Spec. Sens. Acc. AUC
Meningioma (93)/Normal 
(90)
96.2% 84.5% 90.3% 0.957
WHO I(40)/Normal (90) 98.6% 87.5% 95.2% 0.967
WHO II (27)/Normal (90) 98.8% 67.6% 91.8% 0.969
WHO III (26)/Normal (90) 97.9% 72.2% 92.1% 0.901
Classification results Figure 3
Classification results. Logarithm of the quotient Q(A) of P(M|A) over P(N|A) for each of the 183 sera. Normal sera are 
colored black, meningioma sera red. Numbers denote the corresponding WHO grade of each serum. Using a threshold of 1 
(green line), we classify two normal sera, four sera of patients with a common type meningioma, and five sera of patients with 
a WHO grade II and grade III meningioma not correct.BMC Bioinformatics 2006, 7:539 http://www.biomedcentral.com/1471-2105/7/539
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sera of healthy individuals whereas WHO grade III sera
cannot be equally well separated from normal sera. This
finding is reflected in the high AUC values for the detec-
tion of WHO I and II sera and the relatively small AUC
value for the detection of WHOIII sera. Applying unpaired
two-sample t-tests, we found that the differences of the
classification results were statistically significant in each
case (p-value < 0.0002).
Number of antigens required for classification
Next, we computed the minimal number of antigens
required for an optimal classification of low-grade menin-
giomas using the subset selection method described in
'Materials'. Twelve antigens only yielded the best separa-
tion between common type meningiomas and normal
sera with a specificity of 97.5% (95%-CI = [97.4%,
97.7%]), a sensitivity of 91.3% (95%-CI = [90.9%,
91.6%]), and an accuracy of 95.6% (95%-CI = [95.4%,
95.8%]). The corresponding AUC value was 0.971 (95%-
CI = [0.970, 0.971]). Notably, not all of these 12 antigens
are meningioma-specific. One classification result is
shown exemplarily in Figure 4. The specificity, sensitivity,
accuracy, and AUC value as a function of the number of
antigens are provided in Figure 5. This result indicates that
the identification of low-grade meningiomas with high
specificity and sensitivity requires only a subset of all anti-
gens. For comparison, we also carried out the same subset
selection procedure for WHO grade II and III sera. An
optimal classification of WHO grade II meningioma sera
from normal sera requires 36 antigens resulting in a spe-
cificity of 98.9% (95%-CI = [98.8%, 98.9%]), a sensitivity
of 70.1% (95%-CI = [69.6%, 70.6%]), an accuracy of
92.2% (95%-CI = [92.1%, 92.3%]), and an AUC of 0.969
(95%-CI = [0.968, 0.971]). For WHO grade III, 53 anti-
gens are necessary to perform an optimal classification,
yielding a specificity of 97.9% (95%-CI = [97.7%,
98.0%]), a sensitivity of 73.9% (95%-CI = [73.2%,
74.7%]), an accuracy of 92.5% (95%-CI = [92.2%,
92.7%]), and an AUC of 0.902 (95%-CI = [0.900, 0.904]).
The classification results are summarized in Table 3.
Performing the classification of normal sera versus men-
ingioma sera by using just the 8 specific antigens reduced
the accuracy and AUC value significantly to 80% and 0.78
(p-value < 10-10, unpaired two sample Wilcoxon Mann-
Whitney test). Therefore, integration of the non-specific
antigens that contribute additional information makes
the classification significantly more accurate and reliable.
Discussion
The availability of a set of immunogenic antigens is cen-
tral to the idea of using the reactivity pattern to gain
insight into the molecular pathology of tumor develop-
ment. Many antigens formerly considered as tumor spe-
cific antigens also show reactivity with normal sera if the
number of screened normal sera is increased. Scanlan and
co-workers propose that approximately 60% of cancer
antigens react with normal sera [8]. Likewise, the defini-
tion of tumor antigens based on the expression pattern is
less clear than originally proposed. A ubiquitous expres-
sion is reported for more than 10% of cancer testis anti-
gens that should by definition be expressed in testis and
cancer only [9]. Our results are consistent with this data in
that they also show a decreasing number of specific anti-
gens with increasing number of normal sera. A lack of
tumor-specific antigens, i.e. antigens that do not react
with normal sera, is generally thought to impair the devel-
opment of antigens sets useful for tumor analysis. How-
ever, our study shows for the first time that the observed
decrease of the number of specific antigens with increas-
ing number of screened normal sera poses no problem. In
fact, including non-specific antigens in the marker set
improved the accuracy and reliability of the serum based
approach significantly.
We have shown that our diagnosis works especially well
on low-grade (WHO grades I and II) meningioma sera.
That observation can be explained by the fact that the sera
of lower-grade meningiomas show on average an
increased immune response compared to WHO grade III
sera. On averaged, 11.8 of the 57 antigens show reactivity
with WHO grade I sera, 12.1 with WHO grade II sera, and
10.8 with WHO grade II sera. In comparison, normal sera
show an averaged reactivity of only 6.3 antigens per
serum. The decrease of seroreactivity in WHO grade III
tumors may be a result of antigen loss as part of a tumor
escape mechanism [10].
The knowledge of the nature of the antigens is of great
value for a serum-based analysis of human tumors. A
recent study shows a relatively high number of sequences
that do not represent known proteins [5]. These sequences
are thought to mimic immunogenic antigens (mimo-
topes). Without having high homology to known pro-
teins, mimotopes are of no use to provide insight into
tumor development. In our study, 53 of the 57 marker
sequences (93%) are homologous to known proteins as
shown in Table 1.
To further evaluate our set of meningioma-associated
antigens, we computed the overlap of the 57 meningi-
oma-associated antigens with the antigen sets that were
reported for ovarian and prostate cancer types [11,5]. We
found no overlap with any of these antigen sets. An anal-
ysis using PubMed showed that only six meningioma-
associated antigens (10.5%) were immunogenic in other
human cancers. These results indicate that our set of men-
ingioma-associated antigens very likely classifies only sera
of meningioma patients as meningioma sera.BMC Bioinformatics 2006, 7:539 http://www.biomedcentral.com/1471-2105/7/539
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As addressed above, experimental approaches always bear
the possibility of misclassifications. In our study, we mis-
classified a small number of normal sera as meningioma
sera (false positive predictions). This leaves the question
whether a positive prediction of a normal serum is a clas-
sification error or represents a not detected meningioma
patient. According to our protocol, all normal sera were
randomized prior to the experiments. This protocol
excluded the possibility to examine donors of control
blood sera for a potential tumor. It cannot be ruled out
that our test identified a tumor patient that has so far gone
unnoticed. While the annual incidence of meningioma
patients that come to attention in the clinic is approxi-
mately 6 in 105 [12], post mortem studies suggest a true
incidental asymptomatic rate of approximately 1.4% [12].
The comparatively high prevalence results in an excellent
negative predictive value of 0.99 and an acceptable posi-
tive predictive value of 0.56.
Classification results of WHO grade I meningioma Figure 4
Classification results of WHO grade I meningioma. Classification results of low-grade (WHO grade I) meningiomas 
using shrunken antigen subset. Using 12 antigens only, we classify one normal serum and three WHO grade I sera not correct.BMC Bioinformatics 2006, 7:539 http://www.biomedcentral.com/1471-2105/7/539
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MIMM neither depends on a single marker nor represents
a proteomics approach like the serum based diagnosis of
ovarian cancer that triggered a discussion over the general
validity of any diagnostic test based on proteomics [13].
Unlike many proteomics approaches, MIMM utilizes a
small set of proteins only. It is a conservative approach in
that any additional serum analysis helps to improve the
set of antigens that best marks out a cancer patient. MIMM
is an open system that is designed to constantly improve
over time. Once a critical group of antigens is assembled
for a given cancer type, any investigator can add, or if nec-
essary remove, antigens to optimize the power of an anti-
gen set for the characterization of patients with a specific
tumor. In addition, any new serum that is analyzed with
the antigen set improves the predictive value of each anti-
gen of the set. These results indicate that our approach
appears to be well suited to analyse the majority of men-
ingioma patients and to do so specifically efficient for
patients with low-grade meningiomas. Provided these
results can be extended to other tumor types, MIMM rep-
resents a highly promising approach to analyse tumors
that are still in its early stages of development.
Conclusion
We presented a minimally invasive diagnostic framework
based on the classification of tumor antigen patterns in
blood sera using statistical learning techniques. We vali-
dated our approach on meningioma tumors finding that
it is especially suited to detect tumors that are still in their
early stages of development. To further validate and
improve the presented approach, independent training
and test set of appropriate size will be generated. Since our
long term goal is a diagnostic framework for a broad range
of human tumors we will test MIMM on several other
tumor types. Our diagnostic tool may offer the possibility
to screen members of risk groups at regular intervals such
that tumors can be diagnosed immediately after their gen-
esis. It can be expected that the early detection will finally
result in a higher cure- and lower morbidity-rate [14].
Methods
Sera and antigens
By screening a fetal brain expression library with meningi-
oma patients' sera, we previously identified 57 meningi-
oma-associated antigens [7]. Information about the
antigens is provided in Table 1. To establish an analysis
tool to distinguish meningioma patients' sera from con-
trol sera of healthy persons, we used this set of antigens to
screen 93 patients' sera (40 WHO grade I, 27 WHO grade
II, and 26 WHO grade III) and 90 healthy controls with
the spot assay method. Informed consent was obtained
from patients for use of blood sera. The age of the 93
patients ranged between 31 to 85 years, with a mean value
of 60.5 years and a standard deviation of 11.7 years. Out
of 93 patients, 64 were females and 29 were males. All
normal sera were randomly selected. Blood serum was
taken from meningioma patients directly before surgery.
For serum preparation, blood was collected in 10-ml
serum gel monovettes and centrifuged for 10 min. The
serum was stored as 2 ml aliquots at -70°C.
Table 3: Classification results using feature subset selection
Subset Size Spec. Sens. Acc. AUC
Meningioma/Normal 38 96.4% 85.1% 90.6% 0.959
WHO I/Normal 12 97.5% 91.3% 95.6% 0.971
WHO II/Normal 36 98.9% 70.1% 92.2% 0.969
WHO III/Normal 53 97.9% 73.9% 92.5% 0.902
Result of the subset selection Figure 5
Result of the subset selection. Specificity (red), sensitivity 
(green), accuracy (blue), and area under the ROC curve 
(black) as a function of the number of antigens used to sepa-
rate common type meningioma sera from normal sera. With 
a subset size of only 12 antigens the Naïve Bayes approach 
reaches a specificity of 97.5%, a sensitivity of 91.3%, and an 
accuracy of 95.6%. The respective AUC value is 0.971. The 
95% confidence intervals are indicated as vertical black bars.
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Antigen screening
Standard SEREX was used to isolate antigens from a fetal
brain expression library using sera from meningioma
patients. The antigen set was screened by serological spot
assay as described in [7]. In brief, E. coli XL1 blue MRF
were transfected with recombinant lambda phages and
spotted onto nitrocellulose membranes that were pre-
coated with a layer of NZCYM/0.7% agarose/0.25 M
IPTG. After overnight incubation the agarose layer was
removed and membranes were processed for reactivity
with individual sera samples at a 1:100 dilution. The sero-
reactivity patterns of all sera are freely available upon
request.
Classification methods
The screening of the 93 meningioma sera and 90 normal
sera yielded a 183 × 57 binary matrix containing a '1' at
position (i, j) if antigen j has been detected in serum i and
a '0' otherwise. The antigen pattern A of serum i is repre-
sented by the i-th row of the matrix. In order to identify a
suitable classification algorithm, we tested several stand-
ard statistical learning methods like Support Vector
Machines (SVM) or Linear Discriminant Analysis (LDA)
(For a survey of these techniques we refer to [15]. The best
results were obtained with two different Naïve Bayes Clas-
sifiers. The first Bayes approach computes the probabili-
ties  P(M|A) and P(N|A) of a given antigen pattern A
representing a meningioma or a normal serum. If the quo-
tient of P(M|A) over P(N|A) is larger than a chosen thresh-
old t, the serum is classified as meningioma serum and
otherwise as normal serum. A sensible choice for the
threshold parameter t is 1. Increasing the threshold results
in a higher specificity and decreasing the threshold leads
to a higher sensitivity. The second Bayes approach com-
putes the four conditional probabilities P(N|A), P(MI|A),
P(MII|A), and P(MIII|A), where the latter three probabili-
ties represent the three meningioma grades. These three
classes are unified to one 'meningioma class', i.e., if one of
the conditional probabilities P(MI|A),  P(MII|A), or
P(MIII|A) is greater or equals P(N|A), the serum with anti-
gen pattern A is classified as meningioma serum. The clas-
sification methods were evaluated by 10-fold cross
validation. Since different cross validation runs provide
different results, the presented results are averaged over
100 runs. In detail, 100 different, randomly selected par-
titions in 10 parts were carried out and for each of these
100 partitions the classification results were computed.
For each classification, the mean accuracy, sensitivity, and
specificity are provided together with the 95% confidence
intervals (CI).
Subset selection based on mutual information
In order to identify a minimal set of antigens that allows
for an optimal classification we applied a subset selection
method based on mutual information. The mutual infor-
mation is a well known measure in information theory
and was introduced by Shannon [16]. The mutual infor-
mation of an antigen s represents a measure of the infor-
mation content that s provides for the classification task.
More precisely, the mutual information I(X, Y) between
two discrete random variables X and Y is given by H(X) -
H(X|Y). H(X) is the so-called Shannon Entropy defined as
where each xi denotes one of k possible states of the ran-
dom variable X. The conditional entropy H(X|Y) is
defined as
where each yj denotes one of l possible states of the ran-
dom variable Y, p(xi, yj) denotes the joint probability of xi
and yj, and p(xi|yj) denotes the conditional probability of
xi given yj. Thus, the mutual information I(X, Y) can be
considered as the reduction in uncertainty about X due to
the knowledge of Y. In our case, X and Y are binary ran-
dom variables. The two possible states of the random var-
iable X are 'normal' (X = 0) or 'meningioma' (X = 1). If we
are computing the mutual information of antigen s, the
discrete random variable Y  can take the states 's not
detected' (Y = 0) or 's detected' (Y = 1). The higher the
value of the mutual information of antigen s, the more
'valuable' s is for the classification task.
In order to define the minimal subset of antigens, we
tested each possible antigen subset size z ∈ {1, ..., 57}
using 10-fold cross validation. For a given subset size z, we
computed the mutual information of all 57 antigens in
each cross validation run and selected the z antigens with
the highest mutual information to perform the classifica-
tion.
Significance testing using Wilcoxon Mann-Whitney and t-
test
The Wilcoxon Mann-Whitney test [17,18] is a standard
test for comparing two populations. It is applied to test
the null hypothesis that the two tested populations come
from the same distribution against the alternative hypoth-
esis that the populations differ with respect to their loca-
tion only. The nonparametric Wilcoxon Mann-Whitney
test corresponds to the two sample t-test, however, it does
not require that the two populations are normally distrib-
uted. Therefore, the t-test is applied only if the two popu-
lations are normally distributed. The 'normality' was
tested by the Shapiro-Wilk Normality test [19].
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Evaluation of results
To estimate the performance of MIMM, we computed
accuracy
sensitivity
and specificity
of the results. We also computed positive predictive values
(PPV)
and negative predictive value (NPV)
to assess the performance of our approach assuming a rea-
sonable prevalence (PR). In addition, we computed
receiver operator characteristic curves, plots of sensitivity
versus 1-specificity. The value of interest is the area under
the ROC curve, denoted as AUC value. For optimal classi-
fications, AUC equals 1, for random classifications, AUC
equals 0.5. The AUC serves as very meaningful perform-
ance measure.
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